KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Cost of Revenue: 2010-2025

Historic Cost of Revenue for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $10.3 million.

  • Nektar Therapeutics' Cost of Revenue fell 6.50% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 5.64%. This contributed to the annual value of $42.0 million for FY2024, which is 13.49% up from last year.
  • Nektar Therapeutics' Cost of Revenue amounted to $10.3 million in Q3 2025, which was down 0.26% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Cost of Revenue ranged from a high of $17.3 million in Q1 2025 and a low of $5.0 million during Q3 2022.
  • For the 3-year period, Nektar Therapeutics' Cost of Revenue averaged around $10.6 million, with its median value being $10.6 million (2023).
  • As far as peak fluctuations go, Nektar Therapeutics' Cost of Revenue crashed by 33.29% in 2022, and later skyrocketed by 150.02% in 2023.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Cost of Revenue stood at $6.2 million in 2021, then increased by 1.14% to $6.2 million in 2022, then skyrocketed by 69.47% to $10.6 million in 2023, then declined by 18.54% to $8.6 million in 2024, then declined by 6.50% to $10.3 million in 2025.
  • Its Cost of Revenue was $10.3 million in Q3 2025, compared to $10.3 million in Q2 2025 and $17.3 million in Q1 2025.